GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Tangible Book per Share

Sutro Biopharma (Sutro Biopharma) Tangible Book per Share : $2.45 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Sutro Biopharma's tangible book value per share for the quarter that ended in Dec. 2023 was $2.45.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Sutro Biopharma Tangible Book per Share Historical Data

The historical data trend for Sutro Biopharma's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Tangible Book per Share Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial 4.23 7.26 5.45 3.78 2.45

Sutro Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 3.08 2.56 1.85 2.45

Competitive Comparison of Sutro Biopharma's Tangible Book per Share

For the Biotechnology subindustry, Sutro Biopharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Price-to-Tangible-Book falls into.



Sutro Biopharma Tangible Book per Share Calculation

Sutro Biopharma's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(149.649-0-0)/61.0098
=2.45

Sutro Biopharma's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(149.649-0-0)/61.0098
=2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Sutro Biopharma  (NAS:STRO) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Sutro Biopharma Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma (Sutro Biopharma) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Executives
Hans-peter Gerber officer: Chief Scientific Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla officer: Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan officer: Chief Tech Op Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman officer: Chief Medical Officer 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell director, officer: CEO & President 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Nicki Vasquez officer: Chief Port. Strat & Alnce Ofcr C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung officer: Chief Commercial Officer C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam officer: Chief Science Officer PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick officer: Chief People & Comm. Officer NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek director C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121

Sutro Biopharma (Sutro Biopharma) Headlines

From GuruFocus

Sutro Biopharma to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022

Sutro Biopharma to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-23-2022

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

By sperokesalga sperokesalga 02-28-2023